Legal● Neutral for Novartis India

Rs 78,400 vs Rs 7,750 medicine: Novartis, Eli Lilly oppose bid to cut breast cancer drug prices in India

1 source · first seen 13:56 26 Sept · updated 13:56 26 Sept

The brief

Written from 1 report · check the source before you trade

Novartis and Eli Lilly oppose a Kerala High Court petition seeking government intervention to lower breast cancer drug prices
The headline cites prices of Rs 78,400 and Rs 7,750; the summary gives no further details
Any price intervention could affect Novartis India and Indian pharma companies selling cancer treatments

Pick a tag to see all its stories

1 report · earliest 13:56